H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reiterated a Buy rating and an $80.00 price target for Beam Therapeutics Inc (NASDAQ:BEAM), following recent clinical data presentations. The firm views the stock as undervalued, with significant catalysts expected over the next 12 months, including updates on their sickle cell disease and alpha-1 antitrypsin deficiency programs. Despite recent stock fluctuations, Beam Therapeutics has seen a 57% surge over the past year.
Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International Conference - Slideshow
Beam Therapeutics Inc. (BEAM) presented a slideshow at the ATS 2026 International Conference. This article provides access to the slide deck published by the company for the event. The information was released on May 20, 2026.
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value
Beam Therapeutics Inc. (BEAM) is moving its lead gene editing programs in hematology and liver diseases toward regulatory approval. These programs demonstrate strong efficacy and safety, supported by robust biomarker data. The company anticipates achieving accelerated approval, with pricing strategies reflecting the long-term value of these therapies.
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock
Beam Therapeutics Inc (BEAM) is highlighted as a promising gene therapy stock, with its shares significantly appreciating over the past year. The company's BEAM-302 and risto-cel programs are key to its future, with BEAM-302 targeting alpha-1 antitrypsin deficiency and risto-cel addressing sickle cell disease. Analyst H.C. Wainwright has reaffirmed a Buy rating, anticipating a nearly 70% stock price increase.
10 Best Gene Therapy Stocks to Buy in 2026
This article identifies Beam Therapeutics Inc (NASDAQ:BEAM) as one of the top gene therapy stocks to consider in 2026, highlighting its significant stock upside potential of 69.01% and strong hedge fund interest. The company is actively developing several advanced gene therapies, including BEAM-302 for alpha-1 antitrypsin deficiency and Ristoglogene autogetemcel for sickle cell disease, both showing promising clinical trial results and progression towards marketing approval. Beam Therapeutics is noted for its innovative use of base editing techniques to chemically modify DNA without double-stranded breaks.
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path
Beam Therapeutics presented updated Phase 1/2 clinical data for its gene-editing candidate BEAM-302, targeting alpha-1 antitrypsin deficiency (AATD), at the ATS 2026 conference. The company announced plans to pursue an FDA accelerated approval pathway for BEAM-302, with a pivotal expansion phase expected to begin in the second half of 2026 involving around 50 additional patients. The data highlights single-dose cohort safety, durability of efficacy, and reduced human neutrophil elastase activity, suggesting BEAM-302 could offer a one-time treatment solution for the root cause of AATD.
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Beam Therapeutics presented recently reported clinical data from its BEAM-302 Phase 1/2 trial for alpha-1 antitrypsin deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference. The presentation highlighted additional safety results, efficacy durability, and reduction in human neutrophil elastase activity from single-dose cohorts. The company plans to pursue an accelerated approval pathway for BEAM-302 and will expand the ongoing trial with approximately 50 additional patients, aiming to initiate this pivotal cohort in the second half of 2026.
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed?
Beam Therapeutics (BEAM) reported narrowed net losses in Q1 2026 and positive clinical data for BEAM-302, suggesting an accelerated FDA approval pathway. While the base-editing platform shows promising clinical signals, concerns remain regarding long-term safety, regulatory acceptance, and the company's continued net losses. Despite a projected $51.13 fair value, an 83% upside, the investment narrative hinges on converting early successes into approved medicines before cash and competition become significant barriers.
A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention
Beam Therapeutics (BEAM) is drawing attention due to upcoming biomarker data from its BEACON trial and partnerships, despite a recent short-term share price drop. The stock has seen a 56.12% increase over the past year and analysts have a target price of US$51.07, while a community-driven narrative suggests a much higher intrinsic value of $150 per share based on a risk-adjusted Net Present Value model for its lead assets. Investors are advised to consider potential upside, clinical risks, and compare with other investment opportunities.
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout
Beam Therapeutics (BEAM) stock is facing a decline due to profit-taking after a recent earnings rally, a "sell the news" reaction, and its removal from the Russell 3000 Value and Russell Small Cap Complementary Value indices, which has prompted institutional selling. Investor caution ahead of clinical presentations at the RBC Capital Markets Global Healthcare Conference and a trimmed price target from Bernstein are also contributing to the negative sentiment.
BEAM Maintained by Bernstein -- Price Target Lowered to $39.00
Bernstein analyst William Pickering maintained an Outperform rating for Beam Therapeutics (BEAM) but lowered the price target from $40.00 to $39.00. The stock is considered 1.3% overvalued according to GuruFocus's GF Value, despite a strong GF Score of 73/100, which is tempered by insider selling activity totaling $3.7 million in the last three months.
Free genetic tests to spot underdiagnosed Alpha-1 lung and liver risk
Beam Therapeutics has become a key sponsor of AlphaDetect, a nonprofit powered by the Alpha-1 Foundation, to enhance the detection of Alpha-1 Antitrypsin Deficiency (Alpha-1). This collaboration will provide free genetic testing for liver and lung disease patients, offer provider support, and align detection protocols with clinical guidelines, aiming to address the significant underdiagnosis of Alpha-1. The initiative is crucial as over 90% of affected individuals are estimated to be unidentified, impacting those at risk for COPD and liver disease.
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
Beam Therapeutics has become an inaugural industry sponsor for AlphaDetect, a nonprofit powered by the Alpha-1 Foundation. This partnership aims to enhance the detection of Alpha-1 Antitrypsin Deficiency (Alpha-1), a progressive genetic condition, especially in individuals with liver and/or lung disease. AlphaDetect will provide free genetic testing and support for healthcare providers to address the significant underdiagnosis of Alpha-1 and improve early identification.
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts
AlphaDetect has partnered with Beam Therapeutics to improve the detection of Alpha-1 Antitrypsin Deficiency, aiming to increase early diagnosis and treatment outcomes for patients with liver and lung diseases. The partnership includes providing free genetic testing for Alpha-1, collaborating with healthcare providers to enhance detection tools, and promoting adherence to clinical guidelines. This initiative seeks to close the gap in detection rates and support the Alpha-1 community through education and enhanced protocols.
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39
Bernstein has reiterated its "Buy" rating for Beam Therapeutics (BEAM.US) but has reduced the target price to $39. This adjustment indicates a continued positive outlook on the company's stock despite a lower price target.
BEAM's Q1 loss wider than expected, revenues beat estimates
The first-quarter loss for Beam Therapeutics was wider than analysts' expectations, though its revenue surpassed estimates. This financial update provides a mixed picture of the company's performance during the last quarter. Investors and analysts will likely be looking into the specifics of both the expenses leading to the wider loss and the revenue streams that outperformed projections.
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
Beam Therapeutics is evolving from a scientific platform company into a late-stage genetic medicine company with a defined path to commercialization. With a robust cash position of $1.2 billion, the company has funding secured until mid-2029 to advance its pivotal programs, including Risto-cel for sickle cell disease and BEAM-302 for AATD. The article highlights that Beam offers an attractive valuation on a Price/Book basis, especially for investors comfortable with clinical and regulatory risks, given its executable pipeline and strong balance sheet.
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
Beam Therapeutics announced it will present updated biomarker data from its Phase 1/2 BEACON clinical trial for ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress. The data, including two abstracts, are expected to highlight risto-cel's potential to restore red blood cell health and function, with parameters comparable to sickle cell trait, and its ability to induce fetal hemoglobin for improved clinical outcomes. Risto-cel is an investigational base-edited autologous cell therapy designed to increase fetal hemoglobin production in SCD patients.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:30 a.m. ET in New York. The presentation will be webcast live and archived on the company's investor relations website. Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using base editing technology.
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
Beam Therapeutics announced it will present updated biomarker data from its Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease (SCD) at the EHA2026 Congress. The data support risto-cel's potential to restore red blood cell health and function, improve sickling and rheologic parameters, and correlate fetal hemoglobin induction with improved clinical outcomes in SCD. Risto-cel is an investigational autologous cell therapy designed to increase fetal hemoglobin production.
(BEAM) Volatility Zones as Tactical Triggers
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), noting a sentiment shift from near-term strong to long-term positive bias. It highlights an exceptional 57.7:1 risk-reward setup targeting a 17.0% gain. The analysis provides three institutional trading strategies tailored for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy.
Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?
Beam Therapeutics (BEAM) reported a significant revenue increase to $31.74 million in Q1 2026, driven by collaboration milestones, alongside a net loss of $94.32 million. The company is advancing its base-editing pipeline with positive data for BEAM-302 and risto-cel, outlining plans for accelerated approvals in rare diseases. With $1.20 billion in cash and a new $100 million credit facility, Beam is well-positioned to support its programs, making its accelerated approval pathways a key focus for investors.
A Look At Beam Therapeutics (BEAM) Valuation After Earnings Beat And Positive Clinical Updates
Beam Therapeutics (BEAM) recently reported a Q1 revenue beat despite a net loss, accompanied by positive clinical updates that have significantly boosted its stock price within the last month and year. Despite this recent momentum, the company's valuation narrative suggests it is 79% undervalued at $31.47 compared to a $150 fair value, driven by its "molecular pencil" base editing platform and promising clinical trials for BEAM-302 and BEAM-101. The article suggests investors consider these factors to determine if Beam is still an undervalued opportunity.
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics (BEAM) reported a wider-than-expected Q1 2026 loss of 91 cents per share, though revenues of $31.7 million surpassed estimates. The company provided updates on its pipeline, including its lead ex-vivo genome-editing candidate risto-cel for SCD and accelerated approval plans for BEAM-302 for AATD, extending its cash runway into mid-2029. BEAM currently holds a Zacks Rank #4 (Sell).
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics (BEAM) reported a wider-than-expected loss of 91 cents per share in the first quarter of 2026, though its revenues of $31.7 million surpassed the Zacks Consensus Estimate. The company’s cash position is expected to support operations into mid-2029, and it provided updates on its pipeline, including plans to submit a biologics licensing application for risto-cel by the end of 2026 and pursue accelerated approval for BEAM-302.
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics (BEAM) reported a wider-than-expected loss of 91 cents per share in Q1 2026, though revenues of $31.7 million surpassed estimates. The company's pipeline includes risto-cel for SCD, BEAM-301 for GSD1a, BEAM-302 for AATD, and BEAM-103 for SCD, with several clinical updates and regulatory plans announced. Beam holds a Zacks Rank #4 (Sell), while other biotech stocks like Amarin, Indivior Pharmaceuticals, and Liquidia Corporation hold a Zacks Rank #1 (Strong Buy).
Beam Therapeutics (NASDAQ: BEAM) boosts Q1 2026 collaboration revenue, secures new credit facility
Beam Therapeutics reported significantly increased collaboration revenue in Q1 2026, reaching $31.7 million, largely due to a $25 million milestone from its Eli Lilly collaboration. The company narrowed its net loss to $94.3 million and strengthened its liquidity with $1.2 billion in cash and a new $100 million credit facility. Beam advanced its pipeline, including positive clinical data for risto-cel in sickle cell disease and BEAM-302 in alpha-1 antitrypsin deficiency, with plans for regulatory submissions later in 2026.
Beam Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Beam Therapeutics Inc. reported its earnings results for the quarter that ended on December 31. The brief summary was provided by Refinitiv via TradingView News.
Beam Therapeutics (BEAM) Q4 Profit Surprise Challenges Bearish Earnings Narratives
Beam Therapeutics (BEAM) reported a surprising Q4 2025 profit with $114.1 million in revenue and $2.37 basic EPS, overcoming previous losses. While this marked a significant turnaround from earlier quarters, the company still faces a trailing twelve-month loss of $80.0 million, and analysts forecast continued unprofitability despite strong revenue growth projections. The article explores both bullish and bearish perspectives on BEAM's financial outlook, weighing its promising base editing platform against anticipated earnings declines and current valuation.
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $35
JonesTrading has initiated coverage of Beam Therapeutics (BEAM.US) with a "Buy" rating. The firm has set a target price of $35 for the company's stock. This indicates a positive outlook from JonesTrading on Beam Therapeutics' future performance.
Beam Therapeutics Releases Q1 2026 Financial Results
Beam Therapeutics Inc. reported a Q1 2026 net loss of $94.3 million, with a basic and diluted loss of $0.91 per share. Despite the loss, the company generated $31.7 million in revenue, marking a significant 322% increase from Q1 2025, indicating growing commercial traction for its base editing technology and partnerships. This substantial revenue growth suggests validation of Beam's platform in the competitive gene editing landscape.
Beam Therapeutics (BEAM) boosts Q1 revenue and advances late-stage gene-editing pipeline
Beam Therapeutics reported significant progress in its Q1 2026 results, with license and collaboration revenue climbing to $31.7 million and a narrowed net loss of $94.3 million. The company announced major clinical milestones for its gene-editing pipeline, including selecting an optimal dose for BEAM-302 in alpha-1 antitrypsin deficiency and planning a pivotal expansion cohort, and anticipating a biologics license application for risto-cel in sickle cell disease by year-end 2026. With $1.2 billion in cash and marketable securities, Beam projects a cash runway into mid-2029 to support its ongoing clinical development and potential product launches.
Beam targets sickle cell filing as AATD drug heads to pivotal study
Beam Therapeutics reported its Q1 2026 financial results, with a net loss of $94.3 million, and provided key updates on its pipeline. The company selected 60 mg as the optimal biological dose for BEAM-302, with a pivotal cohort planned for H2 2026, and anticipates submitting a Biologics License Application (BLA) for risto-cel, a sickle cell disease treatment, as early as year-end 2026. Beam maintains a strong cash position of $1.2 billion, which is projected to fund operations into mid-2029.
Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure
Beam Therapeutics (BEAM) saw a 5.3% increase in its stock after being featured in TIME's 2026 list of the 10 Most Influential Health & Life Science Companies and a CNBC Mad Money spotlight. Additionally, Vanguard Capital Management disclosed a 5.02% stake in the company. The article discusses how these events, along with positive early clinical data for its base-editing therapies, are influencing investor perception and the company's valuation.
A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress
Beam Therapeutics is gaining attention due to its recognition by TIME as one of 2026’s 10 Most Influential Health & Life Science Companies and promising Phase 1/2 BEACON trial data for sickle cell disease. Despite significant recent share price increases, a widely followed narrative suggests the stock is undervalued, projecting a fair value of $150.00 per share, significantly higher than its current $30.70. However, another market perspective notes the company's P/S ratio is high compared to industry averages, indicating a potentially rich price.
Price-Driven Insight from (BEAM) for Rule-Based Strategy
This article provides a price-driven insight for Beam Therapeutics Inc. (NASDAQ: BEAM) for rule-based trading strategies, highlighting a near-term neutral sentiment amidst mid and long-term strength. It details specific institutional trading strategies including position trading, momentum breakout, and risk hedging, with defined entry, target, and stop-loss levels. The analysis also presents multi-timeframe signal analysis with support and resistance levels generated by AI models.
Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”
Jim Cramer discussed Beam Therapeutics Inc. (NASDAQ: BEAM) as a "speculative situation" on Mad Money. He advised buying only if one believes its formulations can save lives due to its nature as a heavily shorted stock without current earnings. Despite Cramer's prior skepticism, BEAM's stock has risen over 21% since his earlier comments, but the article suggests other AI stocks may offer greater promise and upside potential.
Beam Therapeutics: 2026 TIME100 Most Influential Companies
Beam Therapeutics has been recognized as one of TIME100's Most Influential Companies of 2026 for its innovative base editing technology, which precisely changes single DNA letters without cutting the strand. This approach offers enhanced precision over traditional CRISPR editing. The company has shown promising results in clinical trials, including for sickle cell disease, and its BEAM-302 program for alpha-1 antitrypsin deficiency has received FDA orphan-drug status.
Strong Sickle Cell Data From BEACON Trial Might Change The Case For Investing In Beam Therapeutics (BEAM)
Beam Therapeutics (BEAM) recently released promising Phase 1/2 BEACON trial data for its sickle cell gene-editing therapy, ristoglogene autogetemcel, showing it was well-tolerated and improved anemia markers. These results could significantly enhance Beam Therapeutics' investment narrative, especially as the company plans to use a $500 million credit facility to fund development. While the early success is encouraging, investors should consider risks such as busulfan-related safety, long-term follow-up data, and the company's high valuation relative to current revenues.
Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake
Vanguard Capital Management has reported a 5.02% ownership stake in Beam Therapeutics (NASDAQ: BEAM) through a Schedule 13G SEC filing. The firm beneficially owns 5,122,475 shares, with sole voting power over 745,101 shares and sole dispositive power over all 5,122,475 shares. This filing, dated April 29, 2026, aggregates holdings across various Vanguard affiliates and funds, adhering to SEC disclosure guidelines.
Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM
Concurrent Investment Advisors LLC has invested $2.13 million in Beam Therapeutics Inc. ($BEAM), acquiring 76,825 shares. This investment positions them with approximately 0.08% ownership of the company. Despite recent insider stock sales to cover tax obligations, Beam Therapeutics reported strong Q4 earnings, significantly exceeding revenue and EPS expectations. Analysts currently maintain a "Moderate Buy" consensus rating with an average price target of $49.36, while the stock trades near $30.56.
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
H.C. Wainwright has reiterated its Buy rating on Beam Therapeutics (BEAM.US), maintaining a target price of $80. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study
Beam Therapeutics Inc. (NASDAQ: BEAM) announced encouraging results from its Phase 1/2 BEACON study for ristoglogene autogetemcel (risto-cel), a therapy for severe vaso-occlusive crises in sickle cell disease. The study indicated that risto-cel was well-tolerated and showed promising efficacy, leading to improved parameters for hemolysis, anemia correction, and the absence of vaso-occlusion complications post-transplant. Patients achieved rapid and complete bone marrow reconstitution, with hemoglobin F exceeding 60% and hemoglobin S below 40% in most cases.
10 Best Biotech Stocks with Highest Upside Potential
This article highlights Beam Therapeutics Inc. (NASDAQ: BEAM) as one of the top biotech stocks with high upside potential. It discusses the positive Phase 1/2 BEACON study results for ristoglogene autogetemcel, a therapy for severe vaso-occlusive crises in sickle cell disease, showing promising efficacy and safety. The company specializes in precision genetic medicines and CRISPR-based editing, driving advanced gene therapies.
Beam Therapeutics shows rising relative strength; still shy of key benchmark
The article indicates that Beam Therapeutics is exhibiting increasing relative strength, suggesting a positive trend compared to other stocks or the market. However, it notes that the company has not yet reached a crucial performance benchmark. This implies that while there's improvement, there's still a significant hurdle to overcome to meet key investor expectations or technical indicators.
Beam Therapeutics (BEAM) Q3 2024 earnings summary
Beam Therapeutics (BEAM) reported on its Q3 2024 earnings, highlighting progress in its gene-editing treatments for hematology and liver genetic diseases, with clinical data presented for BEAM-101 and BEAM-302. The company's cash reserves stood at $925.8M as of September 30, 2024, with a projected cash runway into 2027. Future outlook includes initial clinical data for BEAM-302 in 2025 and continued advancement of its ESCAPE technology and pipeline candidates.
Beam Therapeutics (BEAM) H.C. Wainwright 27th Annual Global Investment Conference summary
This article summarizes Beam Therapeutics' presentation at the H.C. Wainwright 27th Annual Global Investment Conference. It highlights the company's base editing platform, its sickle cell disease program (BEAM-101 and Escape), and its competitive positioning, including cost considerations and scalability. The summary also touches upon recent company events and clinical milestones.
Beam Therapeutics (BEAM) Status Update Summary
Beam Therapeutics (BEAM) is focused on developing one-time curative therapies for genetic diseases using precision base editing, an advanced method over traditional CRISPR. The company's pipeline includes BEAM-101 for sickle cell disease, which has shown promising early data in its BEACON trial, as well as BEAM-302, BEAM-301, and BEAM-201 for other serious conditions. Beam has also secured significant strategic partnerships and financing to advance its clinical programs and extend its cash runway.
Beam Therapeutics (BEAM) Q4 2025 earnings summary
Beam Therapeutics announced its Q4 2025 earnings, highlighting the expansion of its liver-targeted portfolio with a new base editing program, BEAM-304, for PKU, and updates on the commercialization of risto-cel for sickle cell disease. The company reported a strong financial position with $1.25 billion in cash and marketable securities and projected a cash runway into mid-2029. Key financial figures included a net income of $244.3 million for Q4 2025 and R&D expenses of $409.6 million for the full year.
Beam Therapeutics (BEAM) Jefferies 2024 Global Healthcare Conference Summary
This article summarizes Beam Therapeutics' presentation at the Jefferies 2024 Global Healthcare Conference, highlighting progress in their sickle cell program with ongoing enrollment in a pivotal trial and expected clinical data later this year. It also details the advancement of their AAT in vivo gene editing program, including planned first patient dosing and anticipated initial clinical data in 2025. Key safety and platform considerations for their LNP formulations and gene editing approach are also discussed.
